SCHEMBL4904022

SCHEMBL4904022

Cc1cccc(C)c1NC(=O)NCCF

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.51
LMNA P02545 3/20 0.50
GFER P55789 1/20 0.50
DRD2 P14416 1/20 0.49
HTR2A P28223 1/20 0.49
HTR2B P41595 1/20 0.49
MAPT P10636 3/20 0.47
ALOX15 P16050 2/20 0.47
PKM P14618 2/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C9 P11712 2/20 0.47
NFKB1 P19838 1/20 0.47
CYP2C19 P33261 1/20 0.47
ITGB3 P05106 1/20 0.46
ITGAV P06756 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29430936 0.83 LMNA (0.54) POLBLMNAGFERDRD2HTR2A
SCHEMBL4893846 0.82 KMT2A (0.55) POLBLMNAMAPTHTTRAB9A
SCHEMBL4898293 0.81 ITGB3 (0.69) POLBMAPTRAB9AKMT2AMEN1
SCHEMBL5470918 0.81 ITGB3 (0.69) POLBLMNAGFERDRD2HTR2A
SCHEMBL13480572 0.80 POLB (0.54) POLBLMNADRD2HTR2AHTR2B
SCHEMBL11054954 0.80 LMNA (0.54) POLBLMNAGFERDRD2HTR2A
SCHEMBL11428483 0.80 LMNA (0.54) POLBLMNAGFERDRD2HTR2A
SCHEMBL30051979 0.79 MAPT (0.67) POLBLMNADRD2HTR2AHTR2B
SCHEMBL11426270 0.78 LMNA (0.52) POLBLMNAGFERDRD2HTR2A
SCHEMBL11219143 0.76 LMNA (0.51) POLBLMNAGFERDRD2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8557853-B2 Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents ALLERGAN, INC. (US) 2013-10-15 US disclosed
US-8557853-B2 Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents ALLERGAN, INC. (US) 2013-10-15 US disclosed
US-8557853-B2 Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents ALLERGAN, INC. (US) 2013-10-15 US disclosed
US-20080194650-A1 ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS ALLERGHAN, INC. 2008-08-14 US disclosed
US-20080194650-A1 ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS ALLERGHAN, INC. 2008-08-14 US disclosed
US-20080194650-A1 ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS ALLERGHAN, INC. 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194650-A1 ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS ADRB2, ADRA2C, ADRA2A POLB 3548/4885LMNA 2913/4885GFER 1906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.